TargetBeta
PADI4
peptidyl arginine deiminase 4 · also PAD, PDI5, PDI4, PADI5 · Peptidyl arginine deiminases
1 program in company-led studies act on PADI4, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| AZD1163 | AstraZeneca | phase 2 | 21 running | PADI2 | a judged reading |
Also acted on by the same programs
Conditions their studies are in
- Arthritis, Rheumatoid, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 12, 2027AZD1163 · AstraZeneca · phase 2 · NCT07276581
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.